CA2453309A1 - Peptide destine a la regulation de l'activateur tissulaire du plasminogene - Google Patents
Peptide destine a la regulation de l'activateur tissulaire du plasminogene Download PDFInfo
- Publication number
- CA2453309A1 CA2453309A1 CA002453309A CA2453309A CA2453309A1 CA 2453309 A1 CA2453309 A1 CA 2453309A1 CA 002453309 A CA002453309 A CA 002453309A CA 2453309 A CA2453309 A CA 2453309A CA 2453309 A1 CA2453309 A1 CA 2453309A1
- Authority
- CA
- Canada
- Prior art keywords
- tpa
- upa
- polypeptide
- tcupa
- fibrinolytic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 35
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 title description 97
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 title description 97
- 229960000187 tissue plasminogen activator Drugs 0.000 title description 91
- 230000033228 biological regulation Effects 0.000 title description 3
- 230000000694 effects Effects 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 17
- 239000003527 fibrinolytic agent Substances 0.000 claims abstract description 15
- 229920001184 polypeptide Polymers 0.000 claims abstract description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 15
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 14
- 230000003480 fibrinolytic effect Effects 0.000 claims abstract description 12
- 102000001938 Plasminogen Activators Human genes 0.000 claims abstract description 9
- 108010001014 Plasminogen Activators Proteins 0.000 claims abstract description 9
- 229940127126 plasminogen activator Drugs 0.000 claims abstract description 9
- 108010023197 Streptokinase Proteins 0.000 claims description 9
- 229960005202 streptokinase Drugs 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 239000003146 anticoagulant agent Substances 0.000 claims description 7
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 230000002537 thrombolytic effect Effects 0.000 claims description 4
- 230000002227 vasoactive effect Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 239000012190 activator Substances 0.000 claims description 2
- 208000032843 Hemorrhage Diseases 0.000 claims 4
- RUXQWZJWMCHCHH-IZZDOVSWSA-N [(e)-1-pyridin-2-ylethylideneamino]urea Chemical compound NC(=O)N\N=C(/C)C1=CC=CC=N1 RUXQWZJWMCHCHH-IZZDOVSWSA-N 0.000 claims 3
- 108010073863 saruplase Proteins 0.000 claims 3
- 230000000153 supplemental effect Effects 0.000 claims 3
- 229960000103 thrombolytic agent Drugs 0.000 claims 3
- 238000011282 treatment Methods 0.000 abstract description 12
- 239000000203 mixture Substances 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 2
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 41
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 41
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 41
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 14
- 229960001802 phenylephrine Drugs 0.000 description 14
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 10
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 10
- 206010047139 Vasoconstriction Diseases 0.000 description 8
- 210000000709 aorta Anatomy 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000025033 vasoconstriction Effects 0.000 description 8
- 102000009123 Fibrin Human genes 0.000 description 7
- 108010073385 Fibrin Proteins 0.000 description 7
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 7
- 102000013566 Plasminogen Human genes 0.000 description 7
- 108010051456 Plasminogen Proteins 0.000 description 7
- 230000009089 cytolysis Effects 0.000 description 7
- 229950003499 fibrin Drugs 0.000 description 7
- 238000010586 diagram Methods 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000009424 thromboembolic effect Effects 0.000 description 6
- 102100033571 Tissue-type plasminogen activator Human genes 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000008602 contraction Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 4
- 229960003318 alteplase Drugs 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000003032 molecular docking Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 108010051412 reteplase Proteins 0.000 description 3
- 229960002917 reteplase Drugs 0.000 description 3
- 108010058207 Anistreplase Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229960000983 anistreplase Drugs 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 208000031169 hemorrhagic disease Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 108010051044 lanoteplase Proteins 0.000 description 2
- 229950010645 lanoteplase Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010014498 Embolic stroke Diseases 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101710172064 Low-density lipoprotein receptor-related protein Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000004179 Plasminogen Activator Inhibitor 2 Human genes 0.000 description 1
- 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 229940122055 Serine protease inhibitor Drugs 0.000 description 1
- 101710102218 Serine protease inhibitor Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 108010078961 duteplase Proteins 0.000 description 1
- 229950004198 duteplase Drugs 0.000 description 1
- 230000003184 effect on constriction Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- -1 for example Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000033885 plasminogen activation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 230000006496 vascular abnormality Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Classifications
-
- H—ELECTRICITY
- H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
- H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
- H05B7/00—Heating by electric discharge
- H05B7/18—Heating by arc discharge
- H05B7/22—Indirect heating by arc discharge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Plasma & Fusion (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Vertical, Hearth, Or Arc Furnaces (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention concerne un polypeptide et son utilisation dans la prévention et/ou le traitement des effets secondaires induits par les activateurs du plasminogène et plus particulièrement tPA ou uPA. L'invention concerne également des compositions combinées et/ou des régimes thérapeutiques faisant intervenir ledit polypeptide et un ou plusieurs activateurs du plasminogène utilisés, ainsi que des méthodes permettant d'obtenir un effet fibrinolytique efficace tout en réduisant les effets secondaires.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90213501A | 2001-07-10 | 2001-07-10 | |
| US09/902,135 | 2001-07-10 | ||
| PCT/US2002/020077 WO2003006042A1 (fr) | 2001-07-10 | 2002-06-24 | Peptide destine a la regulation de l'activateur tissulaire du plasminogene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2453309A1 true CA2453309A1 (fr) | 2003-01-23 |
Family
ID=25415347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002453309A Abandoned CA2453309A1 (fr) | 2001-07-10 | 2002-06-24 | Peptide destine a la regulation de l'activateur tissulaire du plasminogene |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1414479A4 (fr) |
| JP (1) | JP2004534842A (fr) |
| KR (1) | KR20040018442A (fr) |
| BR (1) | BRPI0211234B1 (fr) |
| CA (1) | CA2453309A1 (fr) |
| WO (1) | WO2003006042A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030211095A1 (en) * | 2002-05-08 | 2003-11-13 | Abd. Al-Roof Higazi | Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy |
| EP1496936A4 (fr) * | 2002-03-29 | 2008-05-21 | Univ Johns Hopkins | Thrombolyse hemorragique intraventriculaire |
| CN101808655B (zh) | 2007-07-24 | 2013-08-07 | 迪-药品有限公司 | 衍生自纤溶酶原激活物抑制剂-1的肽和其应用 |
| KR100958999B1 (ko) * | 2007-12-07 | 2010-05-20 | 주식회사 포스코 | 전기로 |
| US9115279B2 (en) | 2013-03-15 | 2015-08-25 | Asahi Kasei Plastics North America, Inc. | Polypropylene compounds with high impact performance and improved stress whitening resistance |
| KR101782406B1 (ko) | 2015-06-11 | 2017-09-27 | 김철민 | 기능성 마네킹 |
| EP3535390A4 (fr) * | 2016-11-02 | 2020-11-25 | Inc. Aronora | Combinaison d'analogue de thrombine e-we et d'un fibrinolytique |
-
2002
- 2002-06-24 JP JP2003511848A patent/JP2004534842A/ja active Pending
- 2002-06-24 CA CA002453309A patent/CA2453309A1/fr not_active Abandoned
- 2002-06-24 WO PCT/US2002/020077 patent/WO2003006042A1/fr not_active Ceased
- 2002-06-24 EP EP02752090A patent/EP1414479A4/fr not_active Withdrawn
- 2002-07-10 BR BRPI0211234-5A patent/BRPI0211234B1/pt unknown
- 2002-07-10 KR KR10-2004-7000327A patent/KR20040018442A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1414479A4 (fr) | 2005-07-13 |
| EP1414479A1 (fr) | 2004-05-06 |
| JP2004534842A (ja) | 2004-11-18 |
| WO2003006042A1 (fr) | 2003-01-23 |
| BRPI0211234B1 (pt) | 2018-04-03 |
| KR20040018442A (ko) | 2004-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5626841A (en) | Use of intra-platelet urokinase-type plasminogen activators for long-term inhibition of thrombosis | |
| EP0307847B1 (fr) | Agent thrombolytique | |
| CN100446810C (zh) | 用于治疗中风的非神经毒性纤溶酶原激活因子 | |
| CA2453309A1 (fr) | Peptide destine a la regulation de l'activateur tissulaire du plasminogene | |
| Bode et al. | Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarction. | |
| US8187592B2 (en) | C1-inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis | |
| EP1507547B1 (fr) | Peptides regulant les activateurs du plasminogene de l'urokinase (upa) et du type de tissu (tpa) et procede d'optimisation de l'efficacite therapeutique | |
| US20060069035A1 (en) | Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy | |
| US7271143B1 (en) | Peptides for regulation of urokinase (uPA) and tissue type (tPA) plasminogen activator and method of optimizing therapeutic efficacy | |
| JPS63119675A (ja) | 変形組織プラスミン活性化剤 | |
| Kaneko et al. | Interactions between the finger and kringle-2 domains of tissue-type plasminogen activator and plasminogen activator inhibitor-1 | |
| Gulba et al. | Low dose urokinase preactivated natural prourokinase for thrombolysis in acute myocardial infarction | |
| AU2002354637A1 (en) | Peptide for regulation of tissue plasminogen activator | |
| Gulba et al. | Potentiative effect of heparin in thrombolytic therapy of evolving myocardial infarction with natural pro-urokinase | |
| Gaffhey | Tissue plasminogen activator for thrombolytic therapy: expectation versus reality | |
| US11154596B2 (en) | Methods for thrombolysis | |
| Tebbe et al. | Thrombolysis using consecutive high dose bolus and infusion of alteplase in a patient with acute massive pulmonary embolism | |
| Kline | Pharmacologic review of thrombolytic agents | |
| WO1995033471A1 (fr) | Thrombolyse intravasculaire | |
| Acar et al. | Thrombolytic treatment in acute myocardial infarction | |
| WO1994003488A1 (fr) | Nouveau peptide | |
| RU2489163C2 (ru) | Применение матриксной металлопротеиназы-10 (ммр-10) для тромболитической терапии | |
| Bajzar et al. | Thrombolysis in children with congenital heart disease | |
| Maksimenko | Experimental combined thrombolytic therapy: The current position and directions of progress |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDC | Correction of dead application (reinstatement) | ||
| FZDE | Dead |